Never Run Out Of Buyers To Sell To.

BreakBio is starting its first clinical trial (IND approved) in its first indication with initial RCT data expected in late 2025. We use high tech personalized drug design then manufacture to treat all solid cancers. Our immunotherapy is designed and manufactured per patient to attack 30 unique targets per patient, identified by an advanced Machine Learning platform. Recent results have created excitement in the cancer vaccine space: for example Moderna’s BTD to prevent cancer recurrence with a personalized cancer vaccine. We are the first company to do mass spec on each patient’s cancer…

Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Estimated OwnershipPrivateMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.